Phaseline

Companies › Acerand Therapeutics (Shanghai)

Acerand Therapeutics (Shanghai): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ACE-86225106
PARP inhibitor
PARP1, PARP2Phase 1Solid Tumor, AdultDec 2028
ACE-232–Phase 1Prostate Cancer (Adenocarcinoma)Dec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06380660ACE-86225106Phase 1Solid Tumor, AdultOncologyDec 2028
NCT06801236ACE-232Phase 1Prostate Cancer (Adenocarcinoma)OncologyDec 2028

Targets

PARP1 (1) PARP2 (1)

Companies with the same targets

AstraZeneca Merck & Co. (MSD) Pfizer Johnson & Johnson (Janssen) GSK Eikon Therapeutics BeiGene Impact Therapeutics pharmaand Allarity Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.